| __timestamp | ADMA Biologics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 5078000000 |
| Thursday, January 1, 2015 | 6745968 | 4717000000 |
| Friday, January 1, 2016 | 8494742 | 5096000000 |
| Sunday, January 1, 2017 | 18092835 | 4986000000 |
| Monday, January 1, 2018 | 22502922 | 4214000000 |
| Tuesday, January 1, 2019 | 25910757 | 3806000000 |
| Wednesday, January 1, 2020 | 35050817 | 3671000000 |
| Friday, January 1, 2021 | 42896889 | 3528000000 |
| Saturday, January 1, 2022 | 52458024 | 3445000000 |
| Sunday, January 1, 2023 | 59020000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and ADMA Biologics, Inc. have showcased contrasting approaches in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Teva's SG&A expenses have seen a steady decline, dropping approximately 31% from 2014's peak. This reflects a strategic shift towards cost optimization amidst market challenges. In contrast, ADMA Biologics has ramped up its SG&A spending by over 1,100% during the same period, signaling aggressive growth and expansion efforts. This divergence highlights the distinct paths these companies are taking in response to industry dynamics. As Teva focuses on efficiency, ADMA is investing heavily in its future, setting the stage for an intriguing competitive landscape in the years to come.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or ADMA Biologics, Inc.
AstraZeneca PLC vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Catalent, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
Breaking Down SG&A Expenses: ADMA Biologics, Inc. vs CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? ADMA Biologics, Inc. or Evotec SE